Roivant Sciences Ltd at Cantor Fitzgerald Global Healthcare Conference Transcript
Good day, I'm Louise Chen, the large-cap pharma, Biopharma and Biotech Analyst here at Cantor. We're very pleased to have with us today, Matthew Gline, who is the CEO of Roivant Pharmaceuticals.
So to start, Matthew for people that are newer to the story, if you could give a brief overview of the company and what your strategic vision is for the next 3 to 5 years for Roivant.
Sure. And first of all, just thank so much for having us. It's great to be here. It's been a good conference already. We're looking forward to it. So really appreciate your hosting. Yes, who are we? So we are a $9.5-ish billion market cap biotech company. We are trying to do what everybody is trying to do, which is to develop medicines that matter. We do that in some unusual ways. We're not set up as a monolithic kind of a command and control organization. We're up as a family of independent biotech companies that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
